My Pharmiweb.com (PharmiWeb)
July 31st, 2009
South San Francisco, Calif. 30 July 2009 Genentech, Inc ., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III study CRUISE showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to central …
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)